论文部分内容阅读
The unsatisfactory results of clinical trials with class-Ⅰ antiarrhythmic drugs have prompted a renaissance of interest in compounds with class-Ⅲ antiarrhythmic action. In the present, we have reevaluated the class-Ⅲ antiarrhythmic ef-
The unsatisfactory results of clinical trials with class-I antiarrhythmic drugs have prompted a renaissance of interest in compounds with class-III antiarrhythmic action. In the present, we have reevaluated the class-III antiarrhythmic ef-